Tag - Myovant Sciences

Developments

Myovant Sciences completes recruitment for Phase 3 endometriosis study

Myovant Sciences (NASDAQ:MYOV) completed patient recruitment for its first of two Phase 3 studies of relugolix combination therapy for the treatment of endometriosis-associated pain. Relugolix is a once daily, oral...

August 20, 2019

Markets

SVB Leerink starts Myovant Sciences at OP; PT $26

SVB Leerink initiated coverage of Myovant Sciences (NYSE:MYOV) with an “outperform” rating and $26 price target. The stock closed at $7 on Aug. 16. “Myovant’s lead product, relugolix, is poised to become the second...

August 19, 2019

Tag - Myovant Sciences

Myovant Sciences completes recruitment for Phase 3 endometriosis study

SVB Leerink starts Myovant Sciences at OP; PT $26

General

More